Matthew K Fust's Net Worth
$26.3 Million
Who is Matthew K Fust?
Matthew K Fust has an estimated net worth of $26.3 Million. This is based on reported shares across multiple companies, which include Neumora Therapeutics, Inc., MACROGENICS INC, Atara Biotherapeutics, Inc., Crinetics Pharmaceuticals, Inc., JAZZ PHARMACEUTICALS INC, Ultragenyx Pharmaceutical Inc., Dermira, Inc., and ONYX PHARMACEUTICALS INC.
SEC CIK
Matthew K Fust's CIK is 0001397266
Past Insider Trading and Trends
2024 was Matthew K Fust's most active year for acquiring shares with 15 total transactions. Matthew K Fust's most active month to acquire stocks was the month of May. 2013 was Matthew K Fust's most active year for disposing of shares, totalling 26 transactions. Matthew K Fust's most active month to dispose stocks was the month of January. 2012 saw Matthew K Fust paying a total of $808,831.84 for 95,508 shares, this is the most they've acquired in one year. In 2013 Matthew K Fust cashed out on 318,107 shares for a total of $9,843,680.97, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Neumora Therapeutics, Inc. (NMRA) Snapshot price: $10.46
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
$11.43 | -$243,923.30 | 20.1K |
Oct 17 - Oct 18
| |||
Form 4
|
∞
| 20.1K |
—
|
—
| 20.1K |
Jun 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 14
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
MACROGENICS INC (MGNX) Snapshot price: $3.1701
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 16
| |||
Form 4
|
—
|
0
|
$24.77 | -$63,908.52 | 500 |
Scheduled
|
Feb 6
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 17
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 20
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 5
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 5
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Atara Biotherapeutics, Inc. (ATRA) Snapshot price: $9.1465
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +137.61% | 150K |
—
|
—
| 259K |
Mar 31
| |||
Form 4
| +109.62% | 57K |
—
|
—
| 109K |
May 31
| |||
Form 4
| +65.08% | 20.5K |
—
|
—
| 52K |
Jun 23
| |||
Form 4
| -29.77% | -13.35K |
$19.50 | -$260,403.00 | 31.5K |
Scheduled
|
Nov 4
| ||
Form 4
| +32.49% | 11K |
—
|
—
| 44.85K |
Jun 8
| |||
Form 4
| +30.94% | 8K |
—
|
—
| 33.85K |
Jun 16
| |||
Form 4
| +18.30% | 4K |
—
|
—
| 25.85K |
Jun 27
| |||
Form 4
| +7.37% | 1.5K |
—
|
—
| 21.85K |
Jun 14
| |||
Form 4
| -36.60% | -11.75K |
$43.57 | -$535,301.02 | 20.35K |
May 14 - May 15
| |||
Form 4
| +5.26% | 1.6K |
—
|
—
| 32.11K |
Feb 15
| |||
Form 4
| +5.54% | 1.6K |
—
|
—
| 30.5K |
Nov 15
| |||
Form 4
| +5.87% | 1.6K |
—
|
—
| 28.9K |
Aug 15
| |||
Form 4
| +22.42% | 5K |
—
|
—
| 27.3K |
Jun 8
| |||
Form 4
| +7.74% | 1.6K |
—
|
—
| 22.3K |
May 15
| |||
Form 4
| +8.40% | 1.6K |
—
|
—
| 20.7K |
Feb 15
| |||
Form 4
| +11.70% | 2K |
—
|
—
| 19.09K |
Jan 3
| |||
Form 4
| +10.34% | 1.6K |
—
|
—
| 17.09K |
Nov 15
| |||
Form 4
| +11.54% | 1.6K |
—
|
—
| 15.49K |
Aug 15
| |||
Form 4
| +13.04% | 1.6K |
—
|
—
| 13.89K |
May 16
| |||
Form 4
| +15.01% | 1.6K |
—
|
—
| 12.29K |
Feb 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 4
| |||
Form 4
| +17.64% | 1.6K |
—
|
—
| 10.68K |
Nov 16
| |||
Form 4
| +21.44% | 1.6K |
—
|
—
| 9.08K |
Aug 17
| |||
Form 4
|
∞
| 7.48K |
—
|
—
| 7.48K |
May 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 21
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Crinetics Pharmaceuticals, Inc. (CRNX) Snapshot price: $50.39
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +18.34% | 3.4K |
—
|
—
| 21.94K |
Jun 7
| |||
Form 4
|
—
|
0
|
$32.53 | -$1,393,175.00 | 18.54K |
Scheduled
|
Mar 20
| ||
Form 4
| +47.86% | 6K |
—
|
—
| 18.54K |
Jun 16
| |||
Form 4
|
—
|
0
|
$11.21 | -$111,189.90 | 12.54K |
Scheduled
|
Jul 13
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 17
| |||
Form 4
|
—
|
0
|
$13.71 | -$211,224.86 | 12.54K |
Scheduled
|
Nov 1
| ||
Form 4
|
—
|
0
|
$13.71 | -$142,625.14 | 12.54K |
Scheduled
|
Sep 8
| ||
Form 4
|
—
|
0
|
$10.75 | -$88,400.00 | 12.54K |
Scheduled
|
Jul 26
| ||
Form 4
|
—
|
0
|
$10.71 | -$87,950.00 | 12.54K |
Scheduled
|
Jul 19
| ||
Form 4
|
—
|
0
|
$11.31 | -$94,000.00 | 12.54K |
Scheduled
|
Jul 12
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 22
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 19
| |||
Form 4
|
—
|
0
|
$12.21 | -$72,065.00 | 12.54K |
Scheduled
|
Dec 16
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 21
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
JAZZ PHARMACEUTICALS INC (JAZZ) Snapshot price: $107.14
EVP, Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +0.65% | 379 |
$1.28 | $485.12 | 58.95K |
Nov 28
| |||
Form 4
| +2.10% | 1.2K |
$6.50 | $7,819.50 | 58.57K |
May 30
| |||
Form 4
| +12.30% | 6.28K |
—
|
—
| 57.37K |
May 16
| |||
Form 4
| +2.79% | 1.39K |
$13.18 | $18,293.84 | 51.09K |
Nov 30
| |||
Form 4
| +66.67% | 19.88K |
—
|
—
| 49.7K |
Jun 6
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||